{"version":"1.0","provider_name":"GenSight Biologics","provider_url":"https:\/\/www.gensight-biologics.com\/fr\/","author_name":"Emmanuelle Lopez","author_url":"https:\/\/www.gensight-biologics.com\/fr\/author\/emmanuelle-lopez\/","title":"GenSight Biologics ren\u00e9gocie ses obligations financi\u00e8res et fait un point sur ses activit\u00e9s - GenSight Biologics","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"WooFoGRmOf\"><a href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/06\/20\/12267\/\">GenSight Biologics ren\u00e9gocie ses obligations financi\u00e8res et fait un point sur ses activit\u00e9s<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/06\/20\/12267\/embed\/#?secret=WooFoGRmOf\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0GenSight Biologics ren\u00e9gocie ses obligations financi\u00e8res et fait un point sur ses activit\u00e9s\u00a0\u00bb &#8212; GenSight Biologics\" data-secret=\"WooFoGRmOf\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.gensight-biologics.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Paris, France, le 20 juin 2024, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la ren\u00e9gociation de certaines obligations financi\u00e8res renfor\u00e7ant ainsi sa [&hellip;]"}